OBJECTIVE: To identify independent contributors of @entity1295 in @entity10632 ( @entity10632 ) @entity1 taking into account clinical, laboratory and psychological features and to explore the potential role of interferon (IFN)-induced gene @entity3035 2,3-dioxygenase ( @entity9218 ), anti-21 hydroxylase [anti-21( @entity2145 )] antibodies and soluble @entity8410 (sBAFF). METHODS: Detailed clinical and laboratory characteristics were recorded for 106 @entity10632 @entity1 . FACIT-F, Zung @entity308 Scale, State-Trait @entity148 Inventory, Eysenck Personality Questionnaire Scale and Athens Insomnia Scale were adopted to assess @entity1295 , @entity308 , @entity148 and @entity25 respectively. Peripheral whole blood expression levels of @entity9218 and type I and II IFN-induced genes were calculated using qRT-PCR. Serum anti-21( @entity2145 ) antibodies and sBAFF levels were determined by a radioimmunoassay and an ELISA, respectively. Univariate and multivariate models were performed to identify @entity1295 determinants. RESULTS: Fatigue was detected in 32 out of 106 (30.2%) of @entity10632 @entity1 . In univariate analysis, @entity1295 was associated with @entity4841 / @entity925 , @entity239 , @entity6383 therapy, both state and trait @entity148 scores, @entity308 and @entity663 , as well as impaired sleep patterns. Multivariate analysis revealed @entity663 [OR=6.9 (95%CI: 1.7-28.0)], @entity308 [OR= 3.0 (95%CI: 0.8-11.0)] and @entity239 [OR= 5.5 (95%CI: 1.1-27.7)], as independent @entity1295 contributors; sBAFF levels, anti-21( @entity2145 ) autoantibodies and @entity9218 transcripts did not differ between fatigued and non-fatigued @entity10632 @entity1 . CONCLUSION: @entity308 , @entity663 and @entity239 play a major role in @entity10632 -associated @entity1295 and should be addressed, in clinical practice, with active collaboration between rheumatologists and mental health professionals. Further studies are warranted in order to explore underlying pathophysiological pathways that might explain @entity1295 in the setting of @entity10632 . This article is protected by copyright. All rights reserved.

Fatigue in XXXX : Clinical, laboratory, psychometric and biological associations.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3035 :: ('CHEBI:28626', 'Chemical') :: ['indoleamine'] @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depression'] @entity239 :: ('MESH:D005356', 'Disease') :: ['fibromyalgia'] @entity8410 :: ('10673', 'Gene') :: ['B-cell activating factor'] @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disturbances'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity6383 :: ('MESH:D006886', 'Chemical') :: ['hydroxychloroquine'] @entity148 :: ('MESH:D001008', 'Disease') :: ['Anxiety', 'anxiety'] @entity663 :: ('MESH:C564323', 'Disease') :: ['neuroticism'] @entity2145 :: ('MESH:C031356', 'Chemical') :: ['OH'] @entity10632 :: ('MESH:D012859', 'Disease') :: ["primary Sjogren's Syndrome", 'pSS'] @entity925 :: ('MESH:D063806', 'Disease') :: ['myalgias'] @entity4841 :: ('MESH:D018771', 'Disease') :: ['arthralgias'] @entity9218 :: ('3620', 'Gene') :: ['IDO-1']
@entity10632 :: (MESH:D012859,Disease) :: ['primary Sjogren's syndrome']
